Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 10;12:920. doi: 10.1038/s41467-021-21159-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Cell proliferation assay in SK-MEL-28 cells treated with increasing amounts of vemurafenib, SJF-0628, or SJF-0661 for 3 days (mean ± SD, n = 3 biologically independent samples). EC₅₀ = 215 ± 1.09 nM, 37 ± 1.2 nM, and 243 ± 1.09 nM, respectively; vemurafenib = blue, SJF-0628 = burgundy, SJF-0661 = purple. b Cell proliferation assay in vemurafenib resistant SK-MEL-239-C4 cells treated with increasing amounts vemurafenib, SJF-0628, or SJF-0661 for 5 days (mean ± SD, n = 3 biologically independent samples); vemurafenib = blue, SJF-0628 = burgundy, SJF-0661 = purple. c Cell proliferation assay in SK-MEL-246 (Class 2) cells treated with increasing amounts vemurafenib, SJF-0628, or SJF-0661 for 5 days (mean ± SD, n = 3 biologically independent samples); vemurafenib = blue, SJF-0628 = burgundy, SJF-0661 = purple. d SJF-0628 EC50 = 218 nM ± 1.06 c,H1666 cells treated with SJF-0628, vemurafenib, or SJF-0661 for 5 days (mean ± SD, n = 3 biologically independent samples); vemurafenib = blue, SJF-0628 = burgundy, SJF-0661 = purple. e Treatment of CAL-12-T cells with vemurafenib, SJF-0628, or SJF-0661 for 5 days shows minimal effect on cell viability (mean ± SD, n = 3 biologically independent samples). f Results of an efficacy study in SK-MEL-246 tumor xenografts implanted in female athymic mice showing tumor regression with 50 mg/kg IP twice daily (mean ± SD, n = 3 biologically independent animals). g Scatter plot result of final tumor volumes of SKMEL-246 xenografts treated with SK-MEL-246 (mean ± SD, n = 3 biologically independent animals). P value calculated by unpaired t-test. Source data are provided as a Source Data file.